| Rank | Clinic Name | Patient Rating | Country | Lead Doctor | experience | Techniques | Best For | Why It’s Ranked | Accreditations |
|---|---|---|---|---|---|---|---|---|---|
| #1 | 4.6 / 5 (436) | Istanbul, Turkey | 37+ years | Umbilical cord-derived mesenchymal stem cell (UC-MSC) transplantation | Genetic ALS cases | A 4-session plan using umbilical cord-derived stem cells (1–2 million cells/kg per session). Treatment includes EMG and genetic analysis to target genetic ALS forms. JCI-accredited hospital. | International Organization for Standardization, Joint Commission International | ||
| #2 | 4.9 / 5 (11) | Monterrey, Mexico | 10+ years | DEZAWA MUSE Cell and Exosome Competence Therapy | — | DEZAWA MUSE therapy delivers 100 million cells and 1 trillion exosomes targeting neuroinflammation. Founder has performed 900+ treatments. | — | ||
| #3 | 4.4 / 5 (3) | Bangkok, Thailand | 7+ years | Fresh, non-frozen umbilical cord-derived mesenchymal stem cells (UC-MSCs) | — | Uses fresh, non-frozen umbilical cord stem cells (UC-MSCs) with high viability. Releases GDNF and BDNF to protect motor neurons. Laboratory operates under ISO 9001:2015, OECD GLP, and ISO/IEC 17025:2017. | ISO 9001:2015 Quality management systems | ||
| #4 | 5.0 / 5 (2) | Bangkok, Thailand | — | — | Peripheral blood stem cell therapy, live cell therapy | — | Offers PBSC therapy with GMP-certified cell rejuvenation, performed in Germany under specialist supervision for ALS and other nerve degenerative diseases. | ISO 9001:2015 Quality management systems | |
| #5 | 5.0 / 5 (1) | Bangkok, Thailand | 15+ years | UC-MSC therapy, intravenous infusion | — | Neurosurgeon-led program for specialist ALS management. Uses GMP-certified umbilical cord stem cells to target inflammation and support neurological function. | ISO 9001:2015 Quality management systems | ||
| #6 | 5.0 / 5 | Monterrey, Mexico | 53+ years | Mesenchymal stem cells (MSC), MUSE cells, exosomes | Exosome-based therapy with direct brain delivery | Exosomes cross the blood-brain barrier to deliver targeted neuroprotection for ALS. MUSE cells can differentiate into neural tissue. 78% of neurodegenerative patients report functional improvement. | — | ||
| #7 | 5.0 / 5 | Medellín, Colombia | 12+ years | Mesenchymal stem cells, exosomes | ALS patients seeking mobility enhancement | Uses high-potency stem cells with a replication factor of 12, significantly more effective than standard treatments. Offers a service guarantee with complimentary re-treatment if results aren't achieved. | — | ||
| #8 | 4.3 / 5 (4) | Kyiv, Ukraine | — | — | Fetal stem cell therapy, intrathecal delivery | — | Holds a patented fetal stem cell method for ALS. Intrathecal delivery option for advanced cases with 4–6 months of stable improvement. | — | |
| #9 | 4.8 / 5 (34) | Eskisehir, Turkey | — | — | Stem cell therapy for ALS (amyotrophic lateral sclerosis) | — | — | International Organization for Standardization, Turkish Medical Association | |
| #10 | 5.0 / 5 (3) | Madrid, Spain | — | — | Stem cell therapy for ALS (amyotrophic lateral sclerosis) | — | — | Joint Commission International , International Organization for Standardization |